期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
骨一方联合低分子肝素对人工全髋关节置换术后深静脉血栓形成的预防作用 被引量:19
1
作者 涂泽松 包杭生 +1 位作者 冯宗权 邱华耀 《广州中医药大学学报》 CAS 2015年第2期199-203,207,共6页
【目的】探讨骨一方联合低分子肝素对人工全髋关节置换(THR)术后深静脉血栓形成(DVT)的预防作用。【方法】采用前瞻随机对照临床试验设计方法,根据性别、年龄、病患部位、就诊时间将100例THR术后病例分成试验组48例和对照组52例。根据... 【目的】探讨骨一方联合低分子肝素对人工全髋关节置换(THR)术后深静脉血栓形成(DVT)的预防作用。【方法】采用前瞻随机对照临床试验设计方法,根据性别、年龄、病患部位、就诊时间将100例THR术后病例分成试验组48例和对照组52例。根据《中国骨科大手术静脉血栓栓塞症预防指南》,2组均给予皮下注射低分子肝素,同时试验组给予骨一方治疗,每日1剂,连续7 d。分别观察2组受试对象试验前后凝血功能、血液流变学指标及伤肢彩色多普勒超声检查结果的变化情况。【结果】(1)试验后,2组全血粘度高切、全血粘度中切、全血粘度低切、血浆粘度等血液流变学指标均显著改善(P<0.05),且试验组的改善作用均优于对照组(P<0.05)。(2)试验后,试验组的凝血酶原时间(PT)、活化部分凝血酶时间(APTT)相对缩短,D-二聚体(D-D)水平显著升高(P<0.05);而对照组的PT、APTT相对延长,D-D水平显著升高(P<0.05);组间比较差异均有统计学意义(P<0.05)。说明骨一方能在一定程度上拮抗低分子肝素对凝血功能的影响而降低诱发出血的可能性。(3)2组试验后伤肢彩色多普勒超声检查结果显示,试验组的伤肢DVT发生率显著低于对照组(P<0.05)。【结论】骨一方联合低分子肝素能够改善人工全髋关节置换术后血液高凝状态,激活纤溶系统,调节血液流变学状态,预防伤肢深静脉血栓形成,同时又能降低诱发出血的可能性,是有效、安全的治疗方案,值得临床推广应用。 展开更多
关键词 骨一方/治疗应用 低分子肝素 人工全髋关节置换术 深静脉血栓形成
下载PDF
Efficacy and safety of Shaoyang Xibi decoction in patients with knee osteoarthritis:a multi-center,single-blind,randomized controlled trial 被引量:11
2
作者 Si Yuhao Ma Yong +5 位作者 Guo Yang Pan Yalan Zheng Suyang Xu Guihua Da Weiwei Xu Lili 《Journal of Traditional Chinese Medicine》 SCIE CAS CSCD 2018年第5期733-739,共7页
PURPOSE: To observe the efficacy and safety of Shaoyang Xibi decoction(SYXBD) in patients with knee osteoarthritis(KOA), and to verify that the theory of "Shaoyang dominating bone" in Traditional Chinese Med... PURPOSE: To observe the efficacy and safety of Shaoyang Xibi decoction(SYXBD) in patients with knee osteoarthritis(KOA), and to verify that the theory of "Shaoyang dominating bone" in Traditional Chinese Medicine(TCM) can be applied to KOA treatment.METHODS: Participants were randomly allocated to two groups: SYXBD(treatment group, n = 66)and Meloxicam(control group, n = 66). Western Ontario and McMaster Universities Osteoarthritis Index(WOMAC) and 36-Item Short Form Health Survey(SF-36) were used to assess efficacy before the treatment and 8 weeks after the treatment.RESULTS: Baseline data before the treatment between the two groups were similar. The WOMAC scores significantly decreased and the SF-36 scores significantly increased after 8-week treatment in both groups compared with before the treatment(P < 0.05). SYXBD significantly decreased pain scores(P < 0.001), physical function scores(P <0.001) and the total scores(P < 0.001) in WOMAC compared to Meloxicam. SYXBD significantly improved physical function(P = 0.021), bodily pain(P = 0.002) and general health(P = 0.014), with no significant difference in role emotional(P = 0.053),role physical(P = 0.517), vitality(P = 0.241), social function(P = 0.712) and mental health(P = 0.800)in SF-36 compared to Meloxicam. No adverse events were reported in the treatment group while13 adverse events happened in the control group during the study.CONCLUSION: SYXBD, prepared based on the theory of "Shaoyang dominating bone", has a better curative efficay and safety in patients with KOA compared with Meloxicam. The TCM theory of "Shaoyang dominating bone" may be useful in KOA treatment. 展开更多
关键词 Osteoarthritis knee therapeutic useS Shaoyang dominating BONE Kidney dominating BONE Shaoyang Xibi decoction
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部